Brigatinib 90mg Tablets

Brigatinib 90mg Tablets is a next-generation tyrosine kinase inhibitor (TKI) engineered to target Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). This medication functions as a multi-targeted inhibitor, effectively blocking the activity of ALK, ROS1, and Insulin-like Growth Factor 1 Receptor (IGF-1R). In patients with specific genetic rearrangements (like EML4-ALK), the ALK protein drives uncontrolled cell proliferation. The drug binds competitively to the ATP-binding pocket of these fusion proteins, shutting down downstream signaling pathways such as PI3K-AKT and RAS-MAPK that are vital for tumor survival. Crucially, it was specifically designed to have broad coverage against various resistance mutations that develop after treatment with first-generation inhibitors (like crizotinib) and to possess high permeability across the blood-brain barrier. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for targeting brain metastases and overcoming drug resistance, offering a robust second line of defense for advanced lung cancer.

The 90mg tablet is the critical “induction” or “lead-in” dosage unit. Because this therapeutic agent can cause early pulmonary toxicity, it utilizes a unique dosing schedule: patients start on 90mg once daily for the first 7 days. If this lead-in dose is well-tolerated, the dose is then escalated to the standard maintenance dose of 180mg daily. This step-up strategy allows the body to adapt to the medication, significantly reducing the risk of severe pneumonitis while ensuring therapeutic levels are reached safely.

Indications / Uses of Brigatinib 90mg Tablets

This product is commonly prescribed for the specialized management of the following malignancies:

• ALK-Positive NSCLC (First-Line): It is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who are ALK-positive as detected by an FDA-approved test and have not received prior systemic therapy.
• ALK-Positive NSCLC (Second-Line): The medication is indicated for patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Key Features

• Broad Mutation Coverage: The primary feature of the tablet is its efficacy against multiple ALK resistance mutations, including those that render first-generation drugs ineffective.
• CNS Penetration: It demonstrates superior intracranial activity, making it highly effective at shrinking or controlling brain metastases, a common site of progression in lung cancer.
• Step-Up Dosing: The 90mg strength facilitates the mandatory 7-day lead-in period designed to mitigate pulmonary side effects.
• Multi-Kinase Inhibition: Beyond ALK, it targets ROS1 and EGFR, providing a wider profile of kinase inhibition.
• Oral Convenience: The once-daily oral regimen (with or without food) supports patient adherence and quality of life.

Storage for Brigatinib 90mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, the medication should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the tablets in their original bottle to protect them from moisture and light. For maximum safety, always store the product in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Brigatinib 90mg Tablets

The administration of Brigatinib 90mg Tablets is associated with a specific risk of Early Onset Pulmonary Events (EOPE). This condition resembles pneumonia (shortness of breath, cough, hypoxia) and typically occurs within the first week of treatment. Strict adherence to the 7-day lead-in at 90mg is mandatory to reduce this risk. Patients must be monitored closely for respiratory symptoms during this first week; if symptoms occur, the dose must be withheld.

Hypertension (high blood pressure) and Bradycardia (slow heart rate) are common; blood pressure and heart rate should be monitored regularly. Visual Disturbances (blurred vision, double vision) and CPK Elevation (muscle enzyme levels indicating muscle stress/pain) are also frequent side effects.

Hyperglycemia: The drug can raise blood sugar levels, so glucose monitoring is necessary, especially in diabetic patients. It can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and the step-up dosing protocol, healthcare providers can safely maximize the survival benefits of Brigatinib 90mg Tablets.